Moderna Tops Revenue Estimates on Strong International COVID Vaccine Sales

What happened

Moderna reported first-quarter 2026 revenue of $389 million, beating consensus estimates of approximately $224 million. Revenue surged 260% year over year, with nearly 80% coming from international markets. Product sales, primarily from COVID-19 vaccines Spikevax and mNexspike, climbed over 300% to $352 million, supported by deliveries under long-term strategic partnerships with government entities outside the United States. The company also generated $37 million from grants, collaborations, and licensing agreements, up 68% from the prior year. On an adjusted basis, Moderna reported a loss of $1.18 per share, better than the consensus estimate of a loss of $3.02. However, the GAAP net loss widened to $1.3 billion from $1 billion a year earlier, impacted by a non-recurring $900 million charge to settle patent litigation with Genevant Sciences and Arbutus Biopharma over COVID-19 vaccine technology. Excluding the settlement, operating expenses declined. Research and development costs fell 24% to $649 million, while selling, general, and administrative expenses dropped 18% to $173 million, reflecting lower employee-related and marketing costs. Cash and cash equivalents stood at $7.5 billion at quarter-end, down from $8.1 billion at year-end 2025.

Why it matters

The strong international performance demonstrates Moderna's strategic shift toward diversifying its revenue base beyond the U.S. market, where COVID-19 vaccine uptake has slowed significantly post-pandemic. Long-term government supply agreements in Canada, Australia, Brazil, Mexico, and the UK are beginning to deliver meaningful revenue, reducing the company's reliance on the domestic market and seasonal demand patterns. The litigation settlement, while costly, removes a major legal overhang related to the company's core mRNA platform technology. Cost-cutting efforts are also gaining traction, positioning Moderna to move closer to its 2028 breakeven target despite ongoing operating losses. For investors, the revenue beat and reaffirmed 2026 guidance provide tangible evidence that Moderna's respiratory vaccine franchise remains commercially viable outside the United States, even as the company works to expand beyond COVID-19 vaccines. The company's ability to manage expenses while investing in its pipeline will be critical to its long-term financial stability.

Bigger picture

Moderna's results reflect the evolving dynamics of the post-pandemic vaccine market. While U.S. demand for COVID-19 vaccines has declined sharply amid changing public health guidance and vaccine skepticism, international markets continue to support demand through government procurement programs. The company's strategy to expand geographically aligns with global public health priorities and provides a more stable revenue base. The biotech sector has faced intense regulatory scrutiny during the second Trump administration, particularly around mRNA technology and vaccine safety. Despite these headwinds, Moderna secured European approval in February 2026 for mCombriax, the first combination COVID-19 and flu vaccine, marking a significant regulatory milestone. The company is also awaiting an August 5, 2026 FDA decision on its standalone flu vaccine, mRNA-1010, following an unusual regulatory dispute earlier this year. Beyond respiratory vaccines, Moderna's oncology pipeline, particularly its personalized cancer therapy intismeran autogene developed with Merck, is generating significant investor interest. The company recently initiated a late-stage study in non-small cell lung cancer and expects Phase 3 melanoma data later in 2026. Analysts estimate Moderna's cancer programs are valued at over $18 billion, underscoring their importance to the company's long-term growth narrative.

What to watch

Key near-term catalysts include the FDA's August 5, 2026 decision on Moderna's standalone flu vaccine, which could enable a commercial launch for the 2026/2027 flu season. Approval would strengthen the company's respiratory franchise and support adoption of its combination flu/COVID vaccine in the U.S. market. Investors should monitor upcoming clinical readouts across Moderna's pipeline, including Phase 3 melanoma data for intismeran autogene expected later in 2026, as well as long-term mid-stage trial data to be presented at the American Society of Clinical Oncology meeting. Results from studies in norovirus vaccines and solid tumor immunotherapies are also anticipated this year. Financially, watch for the timing and impact of the $950 million litigation settlement payment expected in the third quarter of 2026, as well as progress toward the company's 2028 breakeven target. Revenue performance in the second half of 2026, when U.S. COVID-19 vaccine sales typically peak, will provide important insight into demand trends. Moderna's ability to maintain its reaffirmed 10% revenue growth target while controlling costs will be critical to investor confidence.

This article was generated by Quantli AI using publicly available news sources.